47 related articles for article (PubMed ID: 24480357)
1. Development of new LXR modulators that regulate LXR target genes and reduce lipogenesis in human cell models.
Høgmoen Åstrand OA; Gikling I; Sylte I; Rustan AC; Thoresen GH; Rongved P; Kase ET
Eur J Med Chem; 2014 Mar; 74():258-63. PubMed ID: 24480357
[TBL] [Abstract][Full Text] [Related]
2. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and initial biological evaluation of new mimics of the LXR-modulator 22(S)-hydroxycholesterol.
Strand OA; Sandberg M; Sylte I; Görbitz CH; Thoresen GH; Kase ET; Rongved P
Bioorg Med Chem; 2014 Jan; 22(1):643-50. PubMed ID: 24268541
[TBL] [Abstract][Full Text] [Related]
4. Regulation of liver X receptor target genes by 22-functionalized oxysterols. Synthesis, in silico and in vitro evaluations.
Viktorsson EÖ; Gabrielsen M; Kumarachandran N; Sylte I; Rongved P; Åstrand OA; Kase ET
Steroids; 2017 Feb; 118():119-127. PubMed ID: 28011133
[TBL] [Abstract][Full Text] [Related]
5. The liver X receptor modulator 22(S)-hydroxycholesterol exerts cell-type specific effects on lipid and glucose metabolism.
Hessvik NP; Bakke SS; Smith R; Ravna AW; Sylte I; Rustan AC; Thoresen GH; Kase ET
J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):154-64. PubMed ID: 22051079
[TBL] [Abstract][Full Text] [Related]
6. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals.
Kase ET; Thoresen GH; Westerlund S; Højlund K; Rustan AC; Gaster M
Diabetologia; 2007 Oct; 50(10):2171-80. PubMed ID: 17661008
[TBL] [Abstract][Full Text] [Related]
7. LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.
Sim WC; Park S; Lee KY; Je YT; Yin HQ; Choi YJ; Sung SH; Park SJ; Park HJ; Shin KJ; Lee BH
Biochem Pharmacol; 2014 Aug; 90(4):414-24. PubMed ID: 24955981
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).
Li X; Yeh V; Molteni V
Expert Opin Ther Pat; 2010 Apr; 20(4):535-62. PubMed ID: 20302451
[TBL] [Abstract][Full Text] [Related]
9. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO
Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, in vitro and in vivo biological evaluation of new oxysterols as modulators of the liver X receptors.
Åstrand OAH; Viktorsson EÖ; Kristensen AL; Ekeberg D; Røberg-Larsen H; Wilson SR; Gabrielsen M; Sylte I; Rustan AC; Thoresen GH; Rongved P; Kase ET
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):323-330. PubMed ID: 27471149
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012).
Loren J; Huang Z; Laffitte BA; Molteni V
Expert Opin Ther Pat; 2013 Oct; 23(10):1317-35. PubMed ID: 23826715
[TBL] [Abstract][Full Text] [Related]
12. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway.
Ma Y; Xu L; Rodriguez-Agudo D; Li X; Heuman DM; Hylemon PB; Pandak WM; Ren S
Am J Physiol Endocrinol Metab; 2008 Dec; 295(6):E1369-79. PubMed ID: 18854425
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet.
Uebanso T; Taketani Y; Yamamoto H; Amo K; Tanaka S; Arai H; Takei Y; Masuda M; Yamanaka-Okumura H; Takeda E
J Nutr Biochem; 2012 Jul; 23(7):785-90. PubMed ID: 21889884
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors.
Chen Z; Chen H; Zhang Z; Ding P; Yan X; Li Y; Zhang S; Gu Q; Zhou H; Xu J
Eur J Med Chem; 2020 Nov; 206():112793. PubMed ID: 32961480
[TBL] [Abstract][Full Text] [Related]
15. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
[TBL] [Abstract][Full Text] [Related]
16. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells.
Choe SS; Choi AH; Lee JW; Kim KH; Chung JJ; Park J; Lee KM; Park KG; Lee IK; Kim JB
Diabetes; 2007 Jun; 56(6):1534-43. PubMed ID: 17369526
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes.
Zhong D; Huang G; Zhang Y; Zeng Y; Xu Z; Zhao Y; He X; He F
Cell Signal; 2013 Jun; 25(6):1429-37. PubMed ID: 23499676
[TBL] [Abstract][Full Text] [Related]
18. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver.
Anderson SP; Dunn C; Laughter A; Yoon L; Swanson C; Stulnig TM; Steffensen KR; Chandraratna RA; Gustafsson JA; Corton JC
Mol Pharmacol; 2004 Dec; 66(6):1440-52. PubMed ID: 15371561
[TBL] [Abstract][Full Text] [Related]
19. Induction of SREBP-1c mRNA by differentiation and LXR ligand in human keratinocytes.
Yokoyama A; Makishima M; Choi M; Cho Y; Nishida S; Hashimoto Y; Terui T
J Invest Dermatol; 2009 Jun; 129(6):1395-401. PubMed ID: 19242521
[TBL] [Abstract][Full Text] [Related]
20. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
Cannon MV; Yu H; Candido WM; Dokter MM; Lindstedt EL; Silljé HH; van Gilst WH; de Boer RA
Eur J Heart Fail; 2015 Mar; 17(3):273-82. PubMed ID: 25684370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
